(151 days)
Not Found
Yes
The device description explicitly states that it uses "predicted glucose values" to automatically adjust insulin delivery, which strongly suggests the use of predictive algorithms, a common application of ML in medical devices.
Yes
The device is intended for the management of Type 1 diabetes and controls insulin delivery to regulate blood glucose levels, which is a therapeutic purpose.
Yes
The device uses iCGM readings and predicted glucose values to automatically adjust insulin delivery. This involves interpreting glucose data to make treatment decisions, which is a diagnostic function.
Yes
The device description explicitly states "Control-IQ technology (Control-IQ, the device) is a software-only device".
Based on the provided information, the Control-IQ technology itself is not an In Vitro Diagnostic (IVD).
Here's why:
- IVDs are used to examine specimens derived from the human body. The Control-IQ technology is a software-only device that controls an insulin pump based on glucose readings from a continuous glucose monitor (CGM). It does not directly analyze any biological samples.
- The device relies on input from an iCGM. The iCGM (like the Dexcom G6 mentioned as a reference device) is the component that measures glucose levels from interstitial fluid, which is a specimen derived from the human body. The iCGM itself is an IVD.
- Control-IQ processes data and controls insulin delivery. Its function is to interpret the glucose data provided by the iCGM and adjust insulin delivery accordingly. It's a control system, not a diagnostic test.
In summary, Control-IQ technology is a software component that works in conjunction with an IVD (the iCGM) and a medical device (the insulin pump) to manage diabetes. It is not an IVD itself.
No
The provided text does not contain any explicit statements indicating that the FDA has reviewed, approved, or cleared a Predetermined Change Control Plan (PCCP) for this specific device.
Intended Use / Indications for Use
Control-IQ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold.
Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 14 years of age and greater.
Control-IQ technology is intended for single patient use and requires a prescription.
Control-IQ technology is indicated for use with NovoLog or Humalog U-100 insulin.
Product codes
QJI
Device Description
Control-IQ technology (Control-IQ, the device) is a software-only device intended for use by people with diabetes. The device controls insulin delivery from a compatible alternate controller enabled insulin pump (ACE pump) based on inputs provided by a compatible integrated continuous glucose monitor (iCGM) and inputs provided the user (e.g., carbohydrate intake, exercise, and sleep schedule). Control-IQ technology is meant to be installed on a compatible ACE pump.
Control-IQ technology works to control glucose towards a glucose target range of 112.5-160 mg/dL during normal use. Glucose targets are not customizable but can be changed by a user if sleep or exercise modes are set or announced. During sleep mode, this range is changed to 112.5-120 mg/dL, and it is changed to 140-160 mg/dL during exercise mode.
Control-IQ technology includes an integrated feature whereby iCGM values are automatically populated into the glucose field of the integrated bolus calculator when the Control-IO technology is active (i.e., the device is operating in closed-loop mode). This feature is disabled when Control-IQ is turned off.
Using Control-IQ technology requires that users input their weight and their total daily insulin requirement, which should be established with the help of a health care provider before using the device.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
14 years of age and greater.
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Pivotal Study:
The sponsor conducted a controlled, prospective, multicenter pivotal clinical trial consisting of 168 subjects, with 112 subjects in the treatment arm using Control-IQ. The study enrolled subjects diagnosed with type 1 diabetes who were using insulin (either multiple daily injections (MDI) or pump therapy). The study included 6 months of follow-up on all enrolled subjects. The sponsor extended the study protocol for up to 15 months to continue use of Control-IQ in all participants after the cross-over from SAP to Control-IQ in order to gather additional safety data.
Study Feature: Title
Description: The International Diabetes Closed Loop (iDCL) Trial: Pivotal Trial of t:slim X2 with Control-IQ Technology
Study Feature: Summary
Description: A randomized controlled trial of 6 month at home closed loop control (CLC) system vs. sensor-augmented pump (SAP).
Study Feature: Investigational Device
Description: Control-IQ Technology
Study Feature: Objectives
Description: The objective of the study is to assess efficacy and safety of a closed loop system (Control-IQ Technology) in a randomized controlled trial.
Study Feature: Study Design
Description: Randomized Clinical Trial with 2:1 randomization to intervention with the closed loop system vs. sensor-augmented pump for 6 months.
Study Feature: Number of Sites
Description: Seven US clinical sites
Study Feature: Population
Description: There were 31 subjects who were 14 - 18 years old, and 137 subjects >18 years old. The age range was 14-71 years with 33 as the average. 22 of the CLC group were MDI users. The average baseline HbA1c was 7.6.
Key Inclusion Criteria:
• Type 1 Diabetes
• Ages 14 and older
Key Exclusion Criteria:
• Use of any non-insulin glucose-lowering agents except metformin
Sample Size: 168 participants completed the 6-month randomized trial, with 112 in the intervention arm and 56 in the control arm.
Treatment Groups:
Randomized Trial
• Intervention Group: t:slim X2 with Control-IQ Technology and Dexcom G6 iCGM.
• Control Group: Sensor-augmented pump (SAP) with no automated insulin delivery, and Dexcom G6 iCGM.
Study Duration: 6 months for primary study, and up to 15 months total with extension phase
Protocol Overview/Synopsis: Eligible participants not currently using an insulin pump and/or Dexcom G4, G5, or G6 CGM with minimum data requirements participated in a run-in phase of 2 to 8 weeks that was customized based on whether the participant was already a pump or CGM user. Participants who skip or successfully complete the run-in were randomly assigned 2:1 to the CLC group using t:slim X2 with Control-IQ Technology or the SAP group for 6 months.
Pivotal Study Safety Results:
No severe hypoglycemia events occurred in either arm of the study. One diabetic ketoacidosis (DKA) event occurred in the CLC group. This event occurred as the result of an infusion set failure.
Hyperglycemia / ketosis events not meeting the definition of DKA were reportable if they met one of the following criteria:
- evaluation or treatment was obtained at a health care provider facility for an acute event involving hyperglycemia or ketosis
- blood ketone level ≥1.0 mmol/L and communication occurred with a health care ● provider at the time of the event
- blood ketone level ≥3.0 mmol/L, even if there was no communication with a ● health care provider
There were 13 hyperglycemia/ketosis events meeting the above reporting criteria in the CLC arm compared to 2 in the SAP arm.
Subjects in both study arms were provided with blood ketone meters for use at home. There were 14 recorded events (11 subjects) of blood ketone levels >1.0 mmol/L in the CLC arm compared to 15 recorded events (8 subjects) in the SAP arm.
Adverse Events by Study Treatment Group (Pre- and Post-Randomization):
| CLC | SAP | Pre-Randomization | |
|---|---|---|---|
| Hyperglycemia with Ketosis | 12 | 2 | 1 |
| Diabetic Ketoacidosis (DKA) | 1 | - | - |
| Hyperglycemia without Ketosis | 1 | - | - |
| Concussion | 1 | - | - |
| Otitis Externa | 1 | - | - |
| Bypass Surgery | 1 | - | - |
| Total: | 17 | 2 | 1 |
Two unanticipated adverse device effects (UADEs) occurred during the study, both related to device software problems that temporarily suspended the study:
- Inappropriate suspension of basal insulin and inappropriate correction bolus delivery, causing excess insulin delivery (no patient adverse events reported). Corrected with a software patch.
- Incomplete bolus request resulting in hyperglycemia/ketosis for approximately 45 subjects; one subject developed ketosis (2.1 mmol/L) but not DKA. Corrected with a software patch.
Pivotal Study Observed Results:
| Baseline | Post Randomization | |||
|---|---|---|---|---|
| CLC (n=112) | SAP (n=56) | CLC (n=112) | SAP (n=56) | |
| Hours of glucose readings, Median (Q1, Q3)* | 307 (285, 327) | 306 (283, 320) | 4267 (4133, 4348) | 4141 (3922, 4280) |
| HbA1c, Mean ± SD | 7.40 ± 0.96 | 7.40 ± 0.76 | 7.06 ± 0.79 | 7.39 ± 0.92 |
| Mean Glucose (mg/dL), Mean ± SD | 166 ± 32 | 169 ± 25 | 156 ± 19 | 170 ± 25 |
Time spent in different glucose ranges as observed in the pivotal study:
| Baseline | Post Randomization | |||
|---|---|---|---|---|
| CLC (n=112) | SAP (n=56) | CLC (n=112) | SAP (n=56) | |
| % time in range 70-180 mg/dL, Mean ± SD | 61% ± 17% | 59% ± 14% | 71% ± 12% | 59% ± 14% |
| % time below 70 mg/dL, Mean ± SD | 3.58% ± 3.39% | 2.84% ± 2.54% | 1.58% ± 1.15% | 2.25% ± 1.46% |
| % time below 54 mg/dL, Mean ± SD | 0.90% ± 1.36% | 0.56% ± 0.79% | 0.29% ± 0.29% | 0.35% ± 0.32% |
Time spent in different glucose ranges analyzed by time of day, post-randomization:
| Daytime | Nighttime | |||
|---|---|---|---|---|
| CLC (n=112) | SAP (n=56) | CLC (n=112) | SAP (n=56) | |
| Mean Glucose (mg/dL), Mean ± SD | 158 ± 20 | 170 ± 26 | 150 ± 18 | 170 ± 27 |
| % time above 300 mg/dL, Mean ± SD | 2.6% ± 3.8% | 4.8% ± 6.1% | 1.8% ± 2.5% | 4.5% ± 6.3% |
| % time above 250 mg/dL, Mean ± SD | 7.6% ± 7.4% | 12.4% ± 10.5% | 5.4% ± 5.6% | 12.3% ± 10.5% |
| % time above 180 mg/dL, Mean ± SD | 28.6% ± 12.7% | 38.3% ± 15.2% | 22.5% ± 12.5% | 39.1% ± 16.8% |
| % time below 70 mg/dL, Mean ± SD | 1.64% ± 1.2% | 2.21% ± 1.5% | 1.44% ± 1.2% | 2.38% ± 1.9% |
| % time below 60 mg/dL, Mean ± SD | 0.59% ± 0.5% | 0.72% ± 0.6% | 0.60% ± 0.6% | 0.85% ± 0.9% |
| % time below 54 mg/dL, Mean ± SD | 0.28% ± 0.3% | 0.32% ± 0.3% | 0.32% ± 0.3% | 0.44% ± 0.5% |
Safety of CGM Auto-populating Bolus Calculator Feature:
The sponsor analyzed iCGM readings collected during the pivotal study to assess the safety of Control-IQ technology feature whereby iCGM point values are auto-populated into the integrated bolus calculator. iCGM readings up to 5 hours after a bolus was delivered were analyzed.
Two groups of bolus types were compared: (1) in which patients accepted the output of the bolus calculator based on the auto-populated iCGM value, with no modifications, and (2) in which patients manually adjusted the bolus calculation either by manually entering in a glucose value or manually altering the insulin dose recommendation. Results were stratified based on the iCGM value when the bolus was requested.
Post-correction bolus CGM readings (5 hours): based on starting glucose values:
| iCGM Glucose Value | Entry Type | One or More iCGM Reading 250 mg/dL | Automatic (n=2,252) | 5% (4.0, 5.8) | 9% (7.5, 9.8) | 13% (11.9, 14.7) |
| >250 mg/dL | Manual (n=384) | 4% (2.4, 6.5) | 7% (4.5, 9.6) | 9% (6.5, 12.3) |
Differences between post-correction bolus iCGM readings for automatic vs. manually entered glucose values were not significantly different for starting iCGM glucose values below 250 mg/dL. For boluses given when starting iCGM glucose values were >250 mg/dL, the rate at which subjects had five or more consecutive iCGM readings 10 units) and weight requirements (≥55 lbs.).
Postmarket Surveillance Study:
A postmarket surveillance study will be ordered by FDA to confirm understanding of safety and to evaluate:
- What are the rates of diabetic ketoacidosis and severe hypoglycemia when the device is used in the real-world intended use population?
- Are there differences in the rates of diabetic ketoacidosis and severe hypoglycemia between the device users and standard of care?
The postmarket surveillance study will include:
- A prospective single arm cohort study with a minimum of 1,354 subjects being followed for one year to assess differences in the rates of severe hypoglycemia and diabetic ketoacidosis (DKA) between the treatment arm and current standard of care.
- A plan to collect robust data on the rates of severe hypoglycemia and DKA experienced by device users on a monthly basis throughout the study.
- Enrollment targets for specific populations of interest (i.e., pump naïve users, CGM naïve users, pediatric users, users with baseline HbA1c>8.5%).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Key metrics reported are:
- Hours of glucose readings
- HbA1c, Mean ± SD
- Mean Glucose (mg/dL), Mean ± SD
- % time in range 70-180 mg/dL, Mean ± SD
- % time below 70 mg/dL, Mean ± SD
- % time below 54 mg/dL, Mean ± SD
- % time above 300 mg/dL, Mean ± SD
- % time above 250 mg/dL, Mean ± SD
- % time above 180 mg/dL, Mean ± SD
- One or More iCGM Reading
§ 862.1356 Interoperable automated glycemic controller.
(a)
Identification. An interoperable automated glycemic controller is a device intended to automatically calculate drug doses based on inputs such as glucose and other relevant physiological parameters, and to command the delivery of such drug doses from a connected infusion pump. Interoperable automated glycemic controllers are designed to reliably and securely communicate with digitally connected devices to allow drug delivery commands to be sent, received, executed, and confirmed. Interoperable automated glycemic controllers are intended to be used in conjunction with digitally connected devices for the purpose of maintaining glycemic control.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Design verification and validation must include:
(i) An appropriate, as determined by FDA, clinical implementation strategy, including data demonstrating appropriate, as determined by FDA, clinical performance of the device for its intended use, including all of its indications for use.
(A) The clinical data must be representative of the performance of the device in the intended use population and in clinically relevant use scenarios and sufficient to demonstrate appropriate, as determined by FDA, clinical performance of the device for its intended use, including all of its indications for use.
(B) For devices indicated for use with multiple therapeutic agents for the same therapeutic effect (
e.g., more than one type of insulin), data demonstrating performance with each product or, alternatively, an appropriate, as determined by FDA, clinical justification for why such data are not needed.(C) When determined to be necessary by FDA, the strategy must include postmarket data collection to confirm safe real-world use and monitor for rare adverse events.
(ii) Results obtained through a human factors study that demonstrates that an intended user can safely use the device for its intended use.
(iii) A detailed and appropriate, as determined by FDA, strategy to ensure secure and reliable means of data transmission with other intended connected devices.
(iv) Specifications that are appropriate, as determined by FDA, for connected devices that shall be eligible to provide input to (
e.g., specification of glucose sensor performance) or accept commands from (e.g., specifications for drug infusion pump performance) the controller, and a detailed strategy for ensuring that connected devices meet these specifications.(v) Specifications for devices responsible for hosting the controller, and a detailed and appropriate, as determined by FDA, strategy for ensuring that the specifications are met by the hosting devices.
(vi) Documentation demonstrating that appropriate, as determined by FDA, measures are in place (
e.g., validated device design features) to ensure that safe therapy is maintained when communication with digitally connected devices is interrupted, lost, or re-established after an interruption. Validation testing results must demonstrate that critical events that occur during a loss of communications (e.g., commands, device malfunctions, occlusions, etc.) are handled and logged appropriately during and after the interruption to maintain patient safety.(vii) A detailed plan and procedure for assigning postmarket responsibilities including adverse event reporting, complaint handling, and investigations with the manufacturers of devices that are digitally connected to the controller.
(2) Design verification and validation documentation must include appropriate design inputs and design outputs that are essential for the proper functioning of the device that have been documented and include the following:
(i) Risk control measures to address device system hazards;
(ii) Design decisions related to how the risk control measures impact essential performance; and
(iii) A traceability analysis demonstrating that all hazards are adequately controlled and that all controls have been validated in the final device design.
(3) The device shall include appropriate, as determined by FDA, and validated interface specifications for digitally connected devices. These interface specifications shall, at a minimum, provide for the following:
(i) Secure authentication (pairing) to connected devices;
(ii) Secure, accurate, and reliable means of data transmission between the controller and connected devices;
(iii) Sharing of necessary state information between the controller and any connected devices (
e.g., battery level, reservoir level, sensor use life, pump status, error conditions);(iv) Ensuring that the controller continues to operate safely when data is received in a manner outside the bounds of the parameters specified;
(v) A detailed process and procedures for sharing the controller's interface specification with connected devices and for validating the correct implementation of that protocol; and
(vi) A mechanism for updating the controller software, including any software that is required for operation of the controller in a manner that ensures its safety and performance.
(4) The device design must ensure that a record of critical events is stored and accessible for an adequate period to allow for auditing of communications between digitally connected devices, and to facilitate the sharing of pertinent information with the responsible parties for those connected devices. Critical events to be stored by the controller must, at a minimum, include:
(i) Commands issued by the controller, and associated confirmations the controller receives from digitally connected devices;
(ii) Malfunctions of the controller and malfunctions reported to the controller by digitally connected devices (
e.g., infusion pump occlusion, glucose sensor shut down);(iii) Alarms and alerts and associated acknowledgements from the controller as well as those reported to the controller by digitally connected devices; and
(iv) Connectivity events (
e.g., establishment or loss of communications).(5) The device must only receive glucose input from devices cleared under § 862.1355 (integrated continuous glucose monitoring system), unless FDA determines an alternate type of glucose input device is designed appropriately to allow the controller to meet the special controls contained within this section.
(6) The device must only command drug delivery from devices cleared under § 880.5730 of this chapter (alternate controller enabled infusion pump), unless FDA determines an alternate type of drug infusion pump device is designed appropriately to allow the controller to meet the special controls contained within this section.
(7) An appropriate, as determined by FDA, training plan must be established for users and healthcare providers to assure the safety and performance of the device when used. This may include, but not be limited to, training on device contraindications, situations in which the device should not be used, notable differences in device functionality or features compared to similar alternative therapies, and information to help prescribers identify suitable candidate patients, as applicable.
(8) The labeling required under § 809.10(b) of this chapter must include:
(i) A contraindication for use in pediatric populations except to the extent clinical performance data or other available information demonstrates that it can be safely used in pediatric populations in whole or in part.
(ii) A prominent statement identifying any populations for which use of this device has been determined to be unsafe.
(iii) A prominent statement identifying by name the therapeutic agents that are compatible with the controller, including their identity and concentration, as appropriate.
(iv) The identity of those digitally connected devices with which the controller can be used, including descriptions of the specific system configurations that can be used, per the detailed strategy submitted under paragraph (b)(1)(iii) of this section.
(v) A comprehensive description of representative clinical performance in the hands of the intended user, including information specific to use in the pediatric use population, as appropriate.
(vi) A comprehensive description of safety of the device, including, for example, the incidence of severe hypoglycemia, diabetic ketoacidosis, and other relevant adverse events observed in a study conducted to satisfy paragraph (b)(1)(i) of this section.
(vii) For wireless connection enabled devices, a description of the wireless quality of service required for proper use of the device.
(viii) For any controller with hardware components intended for multiple patient reuse, instructions for safely reprocessing the hardware components between uses.
0
EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR Control-IQ Technology DECISION MEMORANDUM
A. DEN Number:
B. Purpose for Submission:
De Novo request for evaluation of automatic class III designation for Control-IQ technology.
C. Manufacturer and Device Name:
Tandem Diabetes Care, Inc. and Control-IO technology
D. Type of Test or Tests Performed:
Not applicable.
E. System Descriptions:
1. Device Description:
Control-IQ technology (Control-IQ, the device) is a software-only device intended for use by people with diabetes. The device controls insulin delivery from a compatible alternate controller enabled insulin pump (ACE pump) based on inputs provided by a compatible integrated continuous glucose monitor (iCGM) and inputs provided the user (e.g., carbohydrate intake, exercise, and sleep schedule). Control-IQ technology is meant to be installed on a compatible ACE pump.
Control-IQ technology works to control glucose towards a glucose target range of 112.5-160 mg/dL during normal use. Glucose targets are not customizable but can be changed by a user if sleep or exercise modes are set or announced. During sleep mode, this range is changed to 112.5-120 mg/dL, and it is changed to 140-160 mg/dL during exercise mode.
Control-IQ technology includes an integrated feature whereby iCGM values are automatically populated into the glucose field of the integrated bolus calculator when the Control-IO technology is active (i.e., the device is operating in closed-loop mode). This feature is disabled when Control-IQ is turned off.
Using Control-IQ technology requires that users input their weight and their total daily insulin requirement, which should be established with the help of a health care provider before using the device.
1
2. Principles of Operation:
Control-IQ technology predicts glucose levels 30 minutes in the future based on prior iCGM readings, insulin delivery history, and user input (e.g., carbohydrate intake, exercise, and sleep schedule) and uses that prediction to adjust insulin delivery. Control-IQ technology can be used to adjust or suspend basal insulin delivery every 5 minutes and automatically deliver correction boluses of insulin based on actual and predicted CGM sensor readings. Users must manually deliver meal boluses they can calculate using the integrated bolus calculator and can manually adjust insulin delivery (change basal rates and deliver insulin boluses) when the Control-IQ technology is active.
3. Modes of Operation:
Does the applicant's device contain the ability to transmit data to a computer, webserver, or mobile device?
Yes _X or No ___________________________________________________________________________________________________________________________________________________________
Does the applicant's device transmit data to a computer, webserver, or mobile device using wireless transmission?
Yes
-
- Software:
FDA has reviewed applicant's Hazard Analysis and Software Development processes for this line of product types:
- Software:
Yes
F. Regulatory Information:
-
- Regulation section: 21 CFR 862.1356
-
- Classification: Class II
- 3 QJI Product code:
-
- Panel: 75. Clinical Chemistry
G. Indications For Use:
-
- Indication(s) for Use:
Control-IQ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) pumps to automatically
- Indication(s) for Use:
2
increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold.
Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 14 years of age and greater.
Control-IQ technology is intended for single patient use and requires a prescription.
Control-IQ technology is indicated for use with NovoLog or Humalog U-100 insulin.
2. Special Conditions for Use Statement(s):
This device is for prescription use only.
This pump is for use only with U-100 Humalog or U-100 NovoLog. Only U-100 Humalog and NovoLog have been tested and found to be compatible for use in the pump. Use of insulin with lesser or greater concentration can result in under delivery or over delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Use of other drugs or medications can damage the pump and result in injury if infused.
The sponsor performed an evaluation of the Control-IQ technology and determined that it may not be safe for use in children under the age of six because Control-IQ technology has lower limits of total daily insulin (≥10 units) and weight requirements (≥55 lbs.). Therefore, the sponsor has included a warning in the labeling for this device as follows:
"Tandem performed an evaluation of the Control-IO technology and determined that it may not be safe for use in children under the age of six because Control-IQ technology has lower limits of total daily insulin and weight requirements. Therefore, Control-IQ technology should not be used in anyone under the age of six years old. Control-IQ technology should also not be used in patients who require less than a total daily insulin dose of 10 units per day or who weigh less than 55 pounds, as those are the required minimum values needed in order for Control-IQ technology to operate safely."
When the device is in closed loop mode, the integrated iCGM auto-population bolus calculator feature of Control-IO automatically enters individual iCGM values (i.e., point values) into the glucose field of the manual bolus calculator (the calculator is not auto populated with iCGM values when in open loop mode). The bolus calculator does not take trend information into account. Because iCGM point values are typically less accurate than self-monitoring blood glucose (SMBG) meter results, using iCGM point values alone without taking trend information into account may result in inaccurate bolus calculations. Therefore, the sponsor has included the following instruction in the labeling for this device as follows:
3
"When the CGM reading is automatically populated into the bolus calculator, only the current CGM reading is used to calculate the correction bolus. The trend arrow is not used in the dose calculation. Speak with your healthcare provider for recommendations on how best to utilize the arrows for your correction bolus dosing."
At the time of device authorization, compatible iCGMs include the following: Dexcom G6 iCGM
H. Standards Documents/Guidance Documents Referenced (if applicable):
ISO 14971:2007: Medical Devices - Application of Risk Management to Medical Devices FDA Recognition No: 5-40
ANSI/AAMI/IEC 62366-1:2015 Medical Devices - Application of usability engineering to medical devices
ANSI/AAMI HE75:2009 Human factors engineering, Design of medical devices
I. Performance Characteristics:
For the purposes of analytical and clinical validation testing, the Control-IQ technology was installed on the Tandem t:slim X2 insulin pump with interoperable technology (DEN180058), which was paired with the Dexcom G6 continuous glucose monitoring system (DEN170088). Details on the performance characteristics of these devices can be found in the public decision summaries for each device.
1. Analytical Performance:
Not applicable.
-
- Comparison Studies:
Not applicable.
- Comparison Studies:
-
- Clinical Studies:
Pivotal Study:
The sponsor conducted a controlled, prospective, multicenter pivotal clinical trial consisting of 168 subjects, with 112 subjects in the treatment arm using Control-IQ. The study enrolled subjects diagnosed with type 1 diabetes who were using insulin (either multiple daily injections (MDI) or pump therapy). The study included 6 months of follow-up on all enrolled subjects. The sponsor extended the study protocol for up to 15 months to continue use of Control-IQ in all participants after the cross-over from SAP to Control-IQ in order to gather additional safety data.
4
Prior to wearing investigational study devices, all study subjects were trained on the device. Subjects who did not currently use an insulin pump or did not use a Dexcom G4. G5, or G6 CGM with readings captured on at least 11 out of the previous 14 days at the time of enrollment were required to participate in a 14-day run-in phase. Subjects who had prior experience with the Tandem t:slim pumps and who had the required amount of CGM data available were given the option to skip the run-in phase. To enter the randomization phase of the trial, participants had to have obtained CGM readings on at least 11 out of the previous 14 days, and pump-naïve patients must have successfully used the study pump each day. Subjects were assessed for their knowledge of pump and CGM use prior to continuing to the randomization phase of the study. Subjects who were new to pump use had their insulin pump settings optimized during the run-in phase. Pump settings were reviewed and further optimized at weeks 2, 13, and 26 of the study.
| Study Feature | Description |
|---|---|
| Title | The International Diabetes Closed Loop (iDCL) Trial: |
| Pivotal Trial of t:slim X2 with Control-IQ Technology | |
| Summary | A randomized controlled trial of 6 month at home |
| closed loop control (CLC) system vs. sensor- | |
| augmented pump (SAP). | |
| Investigational Device | Control-IQ Technology |
| Objectives | The objective of the study is to assess efficacy and |
| safety of a closed loop system (Control-IQ | |
| Technology) in a randomized controlled trial. | |
| Study Design | Randomized Clinical Trial with 2:1 randomization to |
| intervention with the closed loop system vs. sensor- | |
| augmented pump for 6 months. | |
| Number of Sites | Seven US clinical sites |
| Population | There were 31 subjects who were 14 - 18 years old, and |
| 137 subjects >18 years old. The age range was 14-71 | |
| years with 33 as the average. 22 of the CLC group were | |
| MDI users. The average baseline HbA1c was 7.6. |
Key Inclusion Criteria
• Type 1 Diabetes
• Ages 14 and older
Key Exclusion Criteria
• Use of any non-insulin glucose-lowering agents
except metformin |
A summary of the pivotal clinical study is provided in the following table (Control-IQ group abbreviated as CLC (closed-loop control)):
5
| Sample Size | 168 participants completed the 6-month randomized
trial, with 112 in the intervention arm and 56 in the
control arm. |
|-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment Groups | Randomized Trial
• Intervention Group: t:slim X2 with Control-IQ
Technology and Dexcom G6 iCGM.
• Control Group: Sensor-augmented pump (SAP)
with no automated insulin delivery, and Dexcom
G6 iCGM. |
| Study Duration | 6 months for primary study, and up to 15 months total
with extension phase |
| Protocol
Overview/Synopsis | Eligible participants not currently using an insulin
pump and/or Dexcom G4, G5, or G6 CGM with
minimum data requirements participated in a run-in
phase of 2 to 8 weeks that was customized based on
whether the participant was already a pump or CGM
user. Participants who skip or successfully complete the
run-in were randomly assigned 2:1 to the CLC group
using t:slim X2 with Control-IQ Technology or the
SAP group for 6 months. |
Pivotal Study Safety Results:
No severe hypoglycemia events occurred in either arm of the study. One diabetic ketoacidosis (DKA) event occurred in the CLC group. This event occurred as the result of an infusion set failure.
Hyperglycemia / ketosis events not meeting the definition of DKA were reportable if they met one of the following criteria:
- . evaluation or treatment was obtained at a health care provider facility for an acute event involving hyperglycemia or ketosis
- blood ketone level ≥1.0 mmol/L and communication occurred with a health care ● provider at the time of the event
- blood ketone level ≥3.0 mmol/L, even if there was no communication with a ● health care provider
There were 13 hyperglycemia/ketosis events meeting the above reporting criteria in the CLC arm compared to 2 in the SAP arm.
Subjects in both study arms were provided with blood ketone meters for use at home. There were 14 recorded events (11 subjects) of blood ketone levels >1.0 mmol/L in the CLC arm compared to 15 recorded events (8 subjects) in the SAP arm.
6
A summary of all reportable adverse events observed during the study is provided in the following table:
| Post - Randomization | Pre-Randomization | ||
|---|---|---|---|
| CLC | SAP | ||
| Hyperglycemia with Ketosis | 12 | 2 | 1 |
| Diabetic Ketoacidosis (DKA) | 1 | - | - |
| Hyperglycemia without Ketosis | 1 | - | - |
| Concussion | 1 | - | - |
| Otitis Externa | 1 | - | - |
| Bypass Surgery | 1 | - | - |
| Total: | 17 | 2 | 1 |
Table 1: Adverse Events by Study Treatment Group (Pre- and Post-Randomization)
There were two unanticipated adverse device effects (UADEs) during the study, each of which was related to problems with the device software and resulted in the study being temporarily suspended while the problem was investigated and resolved:
-
- Inappropriate suspension of basal insulin and inappropriate correction bolus delivery. There were several instances of excess insulin delivery as a result of this device malfunction, however there were no patient adverse events reported (i.e., no severe hypoglycemia or other adverse events). The device problem was corrected with a software patch during the study.
-
- Incomplete bolus request resulting in hyperglycemia/ketosis. As a result of this device malfunction, approximately 45 subjects experienced inappropriate insulin suspension. In one instance a subject developed ketosis (2.1 mmol/L) as a result, but the patient did not develop DKA. The device problem was corrected with a software patch during the study.
Pivotal Study Observed Results:
The data below describe how the device performed during the pivotal study.
The table below provides a summary of selected metrics for the study run-in period (baseline), and the results after study completion (post randomization).
7
| Baseline | Post Randomization | |||
|---|---|---|---|---|
| CLC | ||||
| (n=112) | SAP | |||
| (n=56) | CLC | |||
| (n=112) | SAP | |||
| (n=56) | ||||
| Hours of glucose readings, | ||||
| Median (Q1, Q3)* | 307 | |||
| (285, 327) | 306 | |||
| (283, 320) | 4267 | |||
| (4133, 4348) | 4141 | |||
| (3922, 4280) | ||||
| HbA1c, | ||||
| Mean ± SD | 7.40 ± 0.96 | 7.40 ± 0.76 | 7.06 ± 0.79 | 7.39 ± 0.92 |
| Mean Glucose (mg/dL), | ||||
| Mean ± SD | 166 ± 32 | 169 ± 25 | 156 ± 19 | 170 ± 25 |
Table 2: Available CGM readings, HbA1c, and mean glucose observed in the pivotal study
*Quartile 1, quartile 3
During the pivotal study, the amount of time subjects spent in different CGM glucose ranges was observed as described in the following tables:
| Baseline | Post Randomization | |||
|---|---|---|---|---|
| CLC | ||||
| (n=112) | SAP | |||
| (n=56) | CLC | |||
| (n=112) | SAP | |||
| (n=56) | ||||
| % time in range 70-180 mg/dL, Mean ± SD | $61% \pm 17%$ | $59% \pm 14%$ | $71% \pm 12%$ | $59% \pm 14%$ |
| % time below 70 mg/dL, Mean ± SD | $3.58% \pm 3.39%$ | $2.84% \pm 2.54%$ | $1.58% \pm 1.15%$ | $2.25% \pm 1.46%$ |
| % time below 54 mg/dL, Mean ± SD | $0.90% \pm 1.36%$ | $0.56% \pm 0.79%$ | $0.29% \pm 0.29%$ | $0.35% \pm 0.32%$ |
Table 3: Time spent in different glucose ranges as observed in the pivotal study
Table 4: Time spent in different glucose ranges analyzed by time of day, postrandomization
| Daytime | Nighttime | |||
|---|---|---|---|---|
| CLC | ||||
| (n=112) | SAP | |||
| (n=56) | CLC | |||
| (n=112) | SAP | |||
| (n=56) | ||||
| Mean Glucose (mg/dL), | ||||
| Mean ± SD | 158 ± 20 | 170 ± 26 | 150 ± 18 | 170 ± 27 |
| % time above 300 mg/dL, | ||||
| Mean ± SD | 2.6% ± | |||
| 3.8% | 4.8% ± | |||
| 6.1% | 1.8% ± | |||
| 2.5% | 4.5% ± | |||
| 6.3% | ||||
| % time above 250 mg/dL, | ||||
| Mean ± SD | 7.6% ± | |||
| 7.4% | 12.4% ± | |||
| 10.5% | 5.4% ± | |||
| 5.6% | 12.3% ± | |||
| 10.5% | ||||
| % time above 180 mg/dL, | ||||
| Mean ± SD | 28.6% ± | |||
| 12.7% | 38.3% ± | |||
| 15.2% | 22.5% ± | |||
| 12.5% | 39.1% ± | |||
| 16.8% |
8
| % time below 70 mg/dL,
| Mean ± SD | 1.64% ± | 2.21% ± | 1.44% ± | 2.38% ± |
|---|---|---|---|---|
| 1.2% | 1.5% | 1.2% | 1.9% | |
| % time below 60 mg/dL, | ||||
| Mean ± SD | 0.59% ± | 0.72% ± | 0.60% ± | 0.85% ± |
| 0.5% | 0.6% | 0.6% | 0.9% | |
| % time below 54 mg/dL, | ||||
| Mean ± SD | 0.28% ± | 0.32% ± | 0.32% ± | 0.44% ± |
| 0.3% | 0.3% | 0.3% | 0.5% |
Safety of CGM Auto-populating Bolus Calculator Feature:
The device includes a feature whereby iCGM values are automatically populated into the glucose field of the integrated bolus calculator when the Control-IQ technology is active (i.e., the device is operating in closed-loop mode). The bolus calculator only uses the iCGM point value. It does not use iCGM trend information. When the Control-IO technology is turned off (i.e., the device is operating in open-loop mode) the CGM autopopulating feature is disabled and users must manually enter a blood glucose value. The iCGM auto-populating feature is an integrated component of the Control-IQ technology device and cannot be used as a stand-alone device.
The sponsor analyzed iCGM readings collected during the pivotal study to assess the safety of Control-IQ technology feature whereby iCGM point values are auto-populated into the integrated bolus calculator. iCGM readings up to 5 hours after a bolus was delivered were analyzed.
Two groups of bolus types were compared: (1) in which patients accepted the output of the bolus calculator based on the auto-populated iCGM value, with no modifications, and (2) in which patients manually adjusted the bolus calculation either by manually entering in a glucose value or manually altering the insulin dose recommendation. Results were stratified based on the iCGM value when the bolus was requested.
The following table presents the rates of low CGM glucose values observed within a 5hour window after a bolus for boluses requested with various initial CGM values.
9
| iCGM Glucose
Value | Entry Type | One or More iCGM
Reading 250 mg/dL | Automatic
(n=2,252) | 5%
(4.0, 5.8) | 9%
(7.5, 9.8) | 13%
(11.9, 14.7) |
| >250 mg/dL | Manual
(n=384) | 4%
(2.4, 6.5) | 7%
(4.5, 9.6) | 9%
(6.5, 12.3) |
Table 5: Post-correction bolus CGM readings (5 hours): based on starting glucose values
In the above table, the differences observed between post-correction bolus iCGM readings for boluses calculated using automatically populated iCGM values and those calculated using manually entered glucose values were not significantly different for starting iCGM glucose values below 250 mg/dL. For boluses given when starting iCGM glucose values were >250 mg/dL, the rate at which subjects had five or more consecutive iCGM readings 10 units) and weight requirements (≥55 lbs.). Therefore, the sponsor has included a warning in the labeling for this device as follows.
"Tandem performed an evaluation of the Control-IQ technology and determined that it may not be safe for use in children under the age of six because Control-IO technology has lower limits of total daily insulin and weight requirements. Therefore, Control-IQ technology should not be used in anyone under the age of six years old. Control-IQ technology should also not be used in patients who require less than a
10
total daily insulin dose of 10 units per day or who weigh less than 55 pounds, as those are the required minimum values needed in order for Control-IQ technology to operate safely."
Postmarket Surveillance Study
There is uncertainty remaining regarding the risk/benefit profile of the device when used in the broader intended use population. While the premarket clinical study provided to support the de novo authorization showed some benefits, the study included device users with relatively high levels of education relative to the general use population, and it was not adequately powered to assess differences in the rates of safety events (e.g., diabetic ketoacidosis and severe hypoglycemia). Furthermore, due to the nature of the study design, the apparent unfavorable difference in the rates of hyperglycemia/ketosis events (not rising to the level of severity of diabetic ketoacidosis) between the treatment and control arms may be due to reporting differences between users rather than a true difference from the device itself.
Accordingly, a postmarket surveillance study will be ordered by FDA to confirm understanding of safety and to evaluate the following question:
- What are the rates of diabetic ketoacidosis and severe hypoglycemia when the ● device is used in the real-world intended use population?
- Are there differences in the rates of diabetic ketoacidosis and severe ● hypoglycemia between the device users and standard of care?
To address these questions, the postmarket surveillance study will include:
- A prospective single arm cohort study with a minimum of 1,354 subjects being ● followed for one year to assess differences in the rates of severe hypoglycemia and diabetic ketoacidosis (DKA) between the treatment arm and current standard of care (based on valid scientific evidence of event rates in current standard of care including patients using multiple daily injection therapy, standalone insulin pumps, or sensor-augmented pumps not including pumps with automated insulin dosing features).
- A plan to collect robust data on the rates of severe hypoglycemia and DKA ● experienced by device users on a monthly basis throughout the study.
- Enrollment targets for specific populations of interest (i.e., pump naïve users, . CGM naïve users, pediatric users, users with baseline HbA1c>8.5%).
4. Other Supportive Data Not Covered Above:
- a. Hazard Analysis:
A comprehensive hazard analysis was provided for this device, in which design inputs and outputs, risks, and risk mitigations for software and interoperable hardware components associated with the safe and effective functioning of the device were reviewed. The hazard analysis provided in this submission accounted for the unique design elements, intended use, and risks of the Control-IQ technology. In particular,
11
this hazard analysis accounted for the risks associated with interoperability between the software device and the hardware device it was installed on, as well as with other third-party digital devices which met predefined criteria but were not specifically identified. This analysis identified hazards which could reasonably be anticipated to impact the proper use of the device, traced all identified risks to adequate design controls, and demonstrated that design features were appropriately implemented and validated.
b. Human Factors:
Human factors validation tests were conducted with the Control-IO technology installed on the t:slim X2 insulin pump with interoperable technology (DEN180058). The summative human factors validation study was performed with sixtv representative participants interactive with the device in a simulated use environment. All study participants received training that was consistent with the training that patients would receive with the commercial product. Usability evaluations assessed comprehension and usability of the device for critical device tasks. Results of the study demonstrated that the device could be used safely by intended users in the intended use environment when used in combination with a digitally connected device.
c. Insulin Compatibility:
The Control-IQ technology is designed to work with either Novolog or Humalog U-100 insulin. These insulins were used in the pivotal clinical study for this device and no other insulins have been tested for use with the device.
Other insulins should not be used with this device. Using insulins with different concentrations or different action profiles (e.g., PK/PD) with this device could result in under delivery or over delivery of insulin. This can cause hypoglycemia or hyperglycemia events.
d. User and Provider Training:
The sponsor provided detailed training materials for healthcare providers who will prescribe this device and manage patients who use this device. The training covers how the device works, details of the clinical study, setting up the device, and information on how to assess patient results with the device.
A training plan for device users was also provided. The plan provides resources for various types of users including new pump users, users switching from a different pump, and users upgrading from a Tandem device. The training plan includes live (in-person or remote) pump training for new pump users (optional for prior pump users) and required online training modules. The training includes initial start-up. troubleshooting, maintenance, and management of the device. Training includes a follow-up 3-5 days after the initial training and subsequent communication with that
12
person's healthcare provider to ensure ongoing follow-up care. Physician and user training as per the sponsor provided training materials is important to ensure safe use of the device.
e. Data Logging:
The sponsor provided validated software protocols which enable the device to record critical events, including information related to its state (e.g., commanded delivery rates/volumes, all algorithm calculations, open loop / closed loop mode, pump behavior, power on/off events), user inputs / key presses, and device settings (e.g., TDI, weight, sleep settings, and preferences). All log entries are time stamped, and the logs are either generated when the events occur or every five minutes in the case of recording algorithm calculations. These protocols were reviewed and found to be adequate.
f. Interoperability:
A plan and approach for interoperability were provided according to the FDA Guidance "Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices - Guidance for Industry and Food and Drug Administration Staff" and determined to be adequate to support and clearly specify expectations, requirements, and interface specifications to potential interoperable devices. In addition, the plans provided by the sponsor covered their approach to working with connected device companies regarding contractual issues, interfaces for data communication and exchange, and post-market reporting procedures and responsibilities (e.g., who is responsible for investigating and reporting complaints, malfunctions, and adverse events).
The sponsor additionally provided validated software protocols intended to ensure secure, accurate, and reliable communication with digital interfacing devices, as well as failsafe design features to mitigate the risks associated with interruption of communication with digitally connected devices. These protocols were reviewed and found to be adequate.
g. Cybersecurity:
Detailed information on cybersecurity of the device was reviewed and found to be acceptable. The sponsor also provided a software bill of materials, which provided details on all software used in the device and the hardware platform that the device was installed on. This included all manufacturer-developed, commercially licensed, open source, and off-the-shelf software components (including firmware as relevant), along with an identification of the hardware runtime environment in which each resides, with relevant version and/or model information, as well as details on whether each component was actively supported by its manufacturer or legacy licensed.
13
J. Proposed Labeling:
The labeling supports the decision to grant the De Novo request for this device.
K. Identified Risks to Health and Mitigations Measures
| Identified Risk | Mitigation Measures |
|---|---|
| Patient harm due to inappropriate drug | |
| delivery | Clinical data demonstrating device performance |
| Certain software validation testing | |
| User training plan | |
| Certain drug compatibility information in | |
| labeling | |
| Risk due to poorer or different | |
| performance in pediatric populations | Clinical data demonstrating device performance |
| in pediatric population | |
| Certain warning statements and precautions in | |
| labeling | |
| Risk due to the inability of the controller | |
| to handle different | |
| pharmacokinetic/pharmacodynamic | |
| characteristics of the drugs | Clinical data demonstrating device performance |
| Drug compatibility information in labeling | |
| User training plan | |
| Human factors testing | |
| Risk due to lack of compatibility of | |
| connected devices | Certain validation of communication |
| specifications, processes, and procedures with | |
| digitally connected devices | |
| Limitations on interoperable devices | |
| Risk of connected devices having | |
| inadequate performance to allow safe use | |
| of the controller | Specifications for performance of connected |
| devices | |
| Certain validation of communication | |
| specifications, processes, and procedures with | |
| digitally connected devices | |
| Limitations on interoperable devices | |
| Failure to report device malfunctions or | |
| adverse events to the device | |
| manufacturer | Plans and procedures for assigning post-market |
| responsibilities. | |
| Risk of latent flaws in software | Robust software validation testing |
| Certain validation of communication | |
| specifications, processes, and procedures with | |
| digitally connected devices | |
| Certain verification and validation of risk | |
| control measures | |
| Failure to provide appropriate treatment | |
| due to loss of communication with | |
| connected devices | Certain verification and validation of risk |
| control measures | |
| Certain validation of communication | |
| specifications, processes, and procedures with | |
| digitally connected devices | |
| Identified Risk | Mitigation Measures |
| Risk due to insecure transmission of data | Certain validation of communication |
| specifications, processes, and procedures with | |
| digitally connected devices | |
| Failure to correctly operate the device | Human factors testing |
| User training plan | |
| Compatible devices listed in labeling | |
| Certain warning statements and precautions in | |
| labeling | |
| Failure to correctly determine the root | |
| cause of device malfunctions | Certain verification and validation of logging |
| capability | |
| Risk due to data transmission | |
| interference/electromagnetic disturbance | Certain verification and validation of electrical |
| safety, electromagnetic compatibility, and | |
| radio frequency wireless testing |
14
L. Benefit/Risk Analysis
Control-IQ technology is intended to be used with a compatible iCGM and ACE pump to automatically increase, decrease, or suspend basal insulin based on current and predicted glucose values. It can also deliver an automatic correction bolus when the glucose value is predicted to exceed a predefined threshold under specific conditions. Glucose targets are not customizable but can be changed by a user if sleep or exercise modes are set or announced. The device is indicated for patients with type 1 diabetes 14 years and older.
Users of the Control-IQ device had a percent time in iCGM range 70-180 mg/dL of 71% in the randomization phase of the trial: however, percent time in iCGM range 70-180 mg/dL is not a validated surrogate marker for clinical diabetes outcomes. Hemoglobin A1c (HbA1c) in the Control-IQ group was slightly improved compared to baseline values, and it does not appear that changes in HbA lc would be worse in patients using Control-IQ compared to patients using SAP. Subjects completed a series of questionnaires and surveys before and after the randomization phase of the study to assess changes in various quality of life aspects. In general. Control-IO users reported reductions in diabetes related distress and fear of hypoglycemia. The device can suspend insulin delivery overnight to reduce the risk of nighttime hypoglycemia, which may provide quality of life improvement to device users and caregivers of device users. These aspects of the data collected indicated there may be significant benefits to patients from using the Control-IQ device.
The study was limited to subjects 14 years and older, thus safety and effectiveness was not. demonstrated in children younger than 14. The device is indicated for use in subjects 14 vears of age and older. Additionally, most of the study population had high socioeconomic and educational status which is likely not generalizable to the intended use population. As a result of the residual uncertainty regarding the generalizability of the study results a postmarket study will be performed for this device to confirm device safety in a broader population.
The risks associated with use of the Control-IQ technology in conjunction with the iCGM and ACE pump include hypoglycemia, severe hypoglycemia, hyperglycemia, and diabetic
15
ketoacidosis (DKA). These events can be attributed to software malfunctions with subsequent over-delivery or inappropriate suspension/under-delivery of insulin commands. Other factors can include erroneous iCGM data transfer with subsequent inappropriate insulin delivery or lack of insulin delivery, interoperable device communication/connectivity issues resulting in temporary loss of Control-IQ use, lack of user knowledge and training leading to device misuse, and a potential increase in mechanical problems that could compromise glycemic control if frequent infusion set failures occur leading to interruption of insulin delivery.
In the clinical study, there was one episode of DKA and no severe hypoglycemia events. The rate of severe hypoglycemia or DKA is difficult to ascertain given these are relatively infrequent events and the study was limited to 168 participants with 6-month device use duration. There appears to be a higher risk of hyperglycemia with ketosis based on the study event criteria; however, it is unclear if the higher rate of hyperglycemia and ketosis events in the CLC arm compared to the SAP arm is directly related to use of the Control-IQ device. The rate of reportable ketosis events as defined in the study protocol was higher in the Control-IO arm: however, the number of measured ketosis events > 1 mmol/L ketones (many of which were not recorded as study reportable events because the subjects did not report the event to a healthcare provider) was similar between both arms. There is uncertainty about whether this is a true difference or a study artifact. Overall, there was one DKA event, caused by infusion site failure, observed in the Control-IQ group, however twice as many participants were randomized to Control-IO compared to SAP and the DKA event may not be directly associated with the device. The rate of other adverse events appears to have been similar between the two study arms when accounting for possible differences in reporting. While the study was not statistically powered to demonstrate statistical superiority, the results suggest that the Control-IQ device may offer several benefits compared to use of a SAP including possible improvements in several measures of diabetic control such as HbA1c and blood glucose concentrations. Given that the study was not adequately powered to assess these specific improvements, or to assess the rates of rare events such as DKA and severe hypoglycemia, collection of additional data in the post-market space can confirm the safety of the device during real-world use.
The sponsor has demonstrated that the probable benefits of Control-IQ technology outweigh the probable risks in light of the special controls for this device tvpe and in combination with general controls. The special controls for this device type are intended to provide reasonable assurance of the safety and effectiveness of the device in the hands of the intended users.
M. Patient Perspectives
Patient perspectives considered include information provided directly to the Agency by patients in written statements and also obtained through discussion with patient advocacy groups at public forums regarding patient experiences with automated insulin dosing systems and digitally connected diabetes devices. This device will allow patients, in conjunction with their healthcare providers, to have more choice in the automated insulin dosing algorithm that integrates with other elements of their diabetes management strategy and works best for their body and their care. In addition, availability of this device will
16
facilitate agile technology development that will ultimately provide innovative diabetes diagnostics and therapies to patients more quickly.
N. Conclusion
The De Novo request is granted and the device is classified under the following and subject to the special controls identified in the letter granting the De Novo request:
Product Code: QJI Device Type: Interoperable automated glycemic controller Class: II (special controls) Regulation: 21 CFR 862.1356